Psychoactive substance use disorder

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%